5345-22-2

Usage

General Description

2-[(6-ethoxy-1,3-benzothiazol-2-yl)sulfanyl]-1-phenylethanone is a chemical compound that is commonly used in research and pharmaceutical applications. It is a thioether derivative of benzothiazole and contains a phenylethanone group. 2-[(6-ethoxy-1,3-benzothiazol-2-yl)sulfanyl]-1-phenylethanone has potential pharmacological properties and has been studied for its anti-inflammatory and antimicrobial activities. It is also known for its ability to inhibit the enzyme monoamine oxidase, which makes it a potential candidate for the development of new pharmaceutical drugs. Additionally, it has been investigated for its potential use in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. Overall, 2-[(6-ethoxy-1,3-benzothiazol-2-yl)sulfanyl]-1-phenylethanone is a versatile compound with diverse pharmacological properties and potential therapeutic applications.

Upstream product

• 51738-10-4 2,2-dibromo-1-(4-nitrophenyl)ethene 
• 50507-86-3 Diethylamide of p-nitrophenylacetic acid 
• 555-16-8 4-nitrobenzaldehdye 

Downstream Products

• 1665-60-7 diethyl-(4-amino-phenethyl)-amine 

Relevant academic research and scientific papers

Synthesis and biological evaluation of new 4β-anilino-4′-O- demethyl-4-desoxypodophyllotoxin derivatives as potential antitumor agents

A series of new 4β-anilino-4′-O-demethyl-4-desoxypodophyllotoxin derivatives were prepared and evaluated for their cytotoxicities against four human cancer cell lines including KB, KB/VCR, A549 and 95D. Most compounds showed better growth-inhibition activities against tested cell lines than that of etoposide (VP-16). Preliminary structure-activity relationships (SARs) were concluded and it indicated that the side chains substituted at 4β position of podophyllotoxin significantly influenced the cytotoxic activity, especially for the drug resistance profile. In vivo studies of compound 26c on highly metastatic human lung cancer xenograft in nude mice showed that it can significantly inhibit tumor growth with administrating by oral route.

Substituted indolines which inhibit receptor tyrosine kinases

Indolinones of the formula having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are: (a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone, and (c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxycarbonyl-2-indolinone.

Substituted indolinones with kinase inhibitory activity

Substituted indolinones of general formula having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. Exemplary compounds are: 3-Z-[1-(4-(N-Benzyl-N-methyl-aminomethyl)-phenylamino)-1-methyl-methylene]-5-a

Indolinones having kinase inhibitory activity

The present invention relates to substituted indolinones of general formula [Figure] wherein R1 to R5, and X are defined as in claim 1, the isomers thereof and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, particularly an inhibitory effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells, pharmaceutical compositions containing these (compounds, their use and processes for preparing them.